

Examiner-Initiated Interview Summary	Application No. 09/618,235	Applicant(s) RUBINGH ET AL.	
	Examiner William W. Moore	Art Unit 1652	

All Participants:

(1) William W. Moore, Examiner.

(2) Ms. Laura L. Frieko, Applicant's Counsel.

Date of Interview: 17 August 2004

Type of Interview:

☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No
 If Yes, provide a brief description: .

Status of Application: _____

(3) _____.

(4) _____.

Time: 4:30PM

Part I.

Rejection(s) discussed:
The rejection of record under 35 U.S.C. section 112

Claims discussed:
1-3, 6-9, 12-15, and 19

Prior art documents discussed:
None


Part II.


SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:
See Continuation Sheet

Part III.

☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.






(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed:

Authorization was requested of, and received from, Applicant's Counsel for the following examiner's amendments the claims:

Claims 6 and 7 will be deleted and claims 8 and 9 will amended to depend from claim 2. The term "moiety" will be deleted after each occurrence of "protease" in all claims and, in claims 1 and 3, the term "microbial" will be inserted before each occurrence of "protease". Claims 2, 8, 9, and 13-15 will be amended to replace the term "nil", referring to structures R1 and R2, with "absent", and to replace the term "nil" with "a covalent bond" with respect to structure X. At the close of claim 2, "is present" will be replaced "is not nil". Claim 12 will be amended to recite, "positions corresponding to positions", before the enumeration of the positions and to recite, "of the subtilisin BPN' amino acid sequence set forth in SEQ ID NO:1", after the enumeration of positions, and claim 19 will be amended to replace "additionally comprising" with "wherein the addition moiety comprises"..


PATENT EXAMINER
UNITED STATES PATENT AND
TRADEMARK OFFICE